On Tuesday, Akero Therapeutics Inc (NASDAQ: AKRO) was 4.72% up from the session before settling in for the closing price of $29.23. A 52-week range for AKRO has been $15.32 – $37.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at -34.94%. With a float of $58.52 million, this company’s outstanding shares have now reached $69.61 million.
The firm has a total of 56 workers. Let’s measure their productivity. In terms of profitability, gross margin is 98.59%, operating margin of -94813.73%, and the pretax margin is -83528.87%.
Akero Therapeutics Inc (AKRO) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Akero Therapeutics Inc stocks. The insider ownership of Akero Therapeutics Inc is 16.16%, while institutional ownership is 92.02%. The most recent insider transaction that took place on Dec 16 ’24, was worth 28,890. Before that another transaction happened on Dec 10 ’24, when Company’s Chief Scientific Officer sold 4,818 for $30.91, making the entire transaction worth $148,934. This insider now owns 178,337 shares in total.
Akero Therapeutics Inc (AKRO) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -34.94% per share during the next fiscal year.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
You can see what Akero Therapeutics Inc (AKRO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 17.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.75, a number that is poised to hit -1.16 in the next quarter and is forecasted to reach -4.74 in one year’s time.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Analysing the last 5-days average volume posted by the [Akero Therapeutics Inc, AKRO], we can find that recorded value of 0.55 million was lower than the volume posted last year of 0.84 million. As of the previous 9 days, the stock’s Stochastic %D was 36.13%. Additionally, its Average True Range was 1.53.
During the past 100 days, Akero Therapeutics Inc’s (AKRO) raw stochastic average was set at 59.61%, which indicates a significant increase from 52.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.53% in the past 14 days, which was lower than the 49.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.83, while its 200-day Moving Average is $25.94. Now, the first resistance to watch is $31.86. This is followed by the second major resistance level at $33.12. The third major resistance level sits at $34.82. If the price goes on to break the first support level at $28.90, it is likely to go to the next support level at $27.20. Should the price break the second support level, the third support level stands at $25.94.
Akero Therapeutics Inc (NASDAQ: AKRO) Key Stats
There are 69,799K outstanding shares of the company, which has a market capitalization of 2.14 billion. As of now, sales total 0 K while income totals -151,760 K. Its latest quarter income was 0 K while its last quarter net income were -72,710 K.
